CLINICAL_TRIALS
trial_result
· 2018-03-01
Clinical Trial Update: A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer [Phase 2]
Summary
A Phase II trial of perifosine following tyrosine kinase inhibitor failure in renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AEterna Zentaris | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED